(CLBT) Cellebrite DI - Ratings and Ratios
Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: IL0011794802
CLBT: Digital Forensics, Data Analysis, Case Management, Training Services
Cellebrite DI Ltd. is a leading developer of solutions for legally sanctioned investigations, with a global presence spanning Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions is designed to facilitate the collection, review, analysis, and management of digital data across the entire investigative lifecycle, supporting a wide range of cases including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
The company's flagship product, Inseyts, is a digital forensics software that enables users to collect and review digital evidence from various digital sources, including computers, mobile devices, and other digital storage media. Inseyts offers advanced data extraction, decoding capabilities, workflows, and automation capabilities, streamlining the investigative process and reducing the time spent on manual data analysis. Additionally, Cellebrite DI offers a range of other solutions, including Cellebrite Pathfinder, which automates data analysis and visualization, reducing the time spent manually reviewing digital evidence.
Cellebrite DI also provides a range of other tools and solutions, including Smart Search, an open source intelligence tool that automates the collection and review of publicly available online data, and Guardian, a case and evidence management solution. The company's digital forensic software is also available for enterprises and service providers, including Inseyts for Enterprise, Endpoint Inspector, and Mobile Now. Furthermore, Cellebrite DI offers professional services, such as training and certification services, to support its customers in using its solutions effectively.
The company's solutions are used by federal, state, and local agencies, as well as enterprises and service providers, to support their investigative and security operations. With its headquarters in Petah Tikva, Israel, Cellebrite DI is a publicly traded company, listed on the NASDAQ stock exchange under the ticker symbol CLBT, and is classified as a common stock with a GICS Sub Industry classification of Application Software. The company's web presence can be found at https://www.cellebrite.com, and its ISIN is IL0011794802.
Additional Sources for CLBT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CLBT Stock Overview
Market Cap in USD | 4,634m |
Sector | Technology |
Industry | Software - Infrastructure |
GiC Sub-Industry | Application Software |
IPO / Inception | 2021-08-31 |
CLBT Stock Ratings
Growth 5y | 59.1% |
Fundamental | 0.82% |
Dividend | - |
Rel. Strength Industry | 800 |
Analysts | 4.75/5 |
Fair Price Momentum | 23.41 USD |
Fair Price DCF | 11.82 USD |
CLBT Dividends
No Dividends PaidCLBT Growth Ratios
Growth Correlation 3m | 90.6% |
Growth Correlation 12m | 93.7% |
Growth Correlation 5y | 26.1% |
CAGR 5y | 22.67% |
CAGR/Mean DD 5y | 0.78 |
Sharpe Ratio 12m | 2.65 |
Alpha | 141.10 |
Beta | 1.02 |
Volatility | 30.03% |
Current Volume | 1221.6k |
Average Volume 20d | 1284.3k |
As of January 21, 2025, the stock is trading at USD 22.78 with a total of 1,221,577 shares traded.
Over the past week, the price has changed by +4.45%, over one month by +1.15%, over three months by +25.51% and over the past year by +155.10%.
Neither. Based on ValueRay Fundamental Analyses, Cellebrite DI is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 0.82 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLBT as of January 2025 is 23.41. This means that CLBT is currently overvalued and has a potential downside of 2.77%.
Cellebrite DI has received a consensus analysts rating of 4.75. Therefor, it is recommend to buy CLBT.
- Strong Buy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CLBT Cellebrite DI will be worth about 26.1 in January 2026. The stock is currently trading at 22.78. This means that the stock has a potential upside of +14.35%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 23.3 | 2.2% |
Analysts Target Price | 23.3 | 2.2% |
ValueRay Target Price | 26.1 | 14.4% |